Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Behavioral Science Banner Maps The Future Of GSK Consumer Business

This article was originally published in The Tan Sheet

Executive Summary

Roger Scarlett-Smith, the new head of GlaxoSmithKline's North American Consumer Healthcare business, believes a nonprescription statin is probably inevitable in the U.S., and his firm still wants to be in early on that opportunity

You may also be interested in...



First EU Centralized Switch Goes To Alli, Could Spark More Applications

Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.

First EU Centralized Switch Goes To Alli, Could Spark More Applications

Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.

GSK Alli Strategy Relies Even More On Users Spreading The Word

Heading into its second year selling weight-loss drug alli over the counter, GlaxoSmithKline wants users to do the talking

Related Content

Topics

UsernamePublicRestriction

Register

PS101811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel